Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
Public ClinicalTrials.gov record NCT03693430. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Two-year Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity
Study identification
- NCT ID
- NCT03693430
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Enrollment
- 304 participants
Conditions and interventions
Conditions
Interventions
- Placebo (Semaglutide) Drug
- Semaglutide Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 4, 2018
- Primary completion
- Jan 28, 2021
- Completion
- Mar 22, 2021
- Last update posted
- Jul 5, 2023
2018 – 2021
United States locations
- U.S. sites
- 15
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novo Nordisk Investigational Site | Birmingham | Alabama | 35222 | — |
| Novo Nordisk Investigational Site | Los Angeles | California | 90057 | — |
| Novo Nordisk Investigational Site | Aurora | Colorado | 80045 | — |
| Novo Nordisk Investigational Site | Golden | Colorado | 80401 | — |
| Novo Nordisk Investigational Site | Waterbury | Connecticut | 06708 | — |
| Novo Nordisk Investigational Site | Jacksonville | Florida | 32205 | — |
| Novo Nordisk Investigational Site | Ocala | Florida | 34471 | — |
| Novo Nordisk Investigational Site | City of Saint Peters | Missouri | 63303 | — |
| Novo Nordisk Investigational Site | Butte | Montana | 59701 | — |
| Novo Nordisk Investigational Site | Albany | New York | 12203 | — |
| Novo Nordisk Investigational Site | Rochester | New York | 14609 | — |
| Novo Nordisk Investigational Site | Kingsport | Tennessee | 37660 | — |
| Novo Nordisk Investigational Site | Austin | Texas | 78731 | — |
| Novo Nordisk Investigational Site | Round Rock | Texas | 78681 | — |
| Novo Nordisk Investigational Site | Arlington | Virginia | 22206 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03693430, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 5, 2023 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03693430 live on ClinicalTrials.gov.